Innospera
- Biotech or pharma, therapeutic R&D
Innospera Pharma is a near-clinical stage biopharmaceutical company (anticipated Q4 2025) developing a pipeline of proprietary small molecule GPR84 and GPR40 modulators. Our lead program focuses on Idiopathic Pulmonary Fibrosis (IPF), with broader potential across inflammatory and metabolic disorders.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}